Skip to main content
Parathyroid Disorders
resource center
Menu
Menu
Main navigation
Home
Featured Diseases & Conditions
Allergic Asthma
Alopecia Areata
Atopic Dermatitis Care
Alzheimer Disease
Chronic Kidney Disease
COVID-19
Depression Care
Emergency Medicine
Eosinophilic Disease
HIV Management
HIV Prevention
Multicancer Early Detection
Prostate Cancer
Scleroderma
Resources
AbbVie Partner Spotlight
Commentary
Disease State Directory
FDA Alerts
News
Pearls
Podcasts
Polls
Q&As
Quizzes
Slideshows
The 411 on a GLP-1
Videos
Events & Education
ACAAI Annual Scientific Meeting
ACR Convergence
Consultant360's Practical Updates in Primary Care
CME
International AIDS Conference
Publications
Advertising With Consultant360
Author Guidelines
Consultant Archive
Consultant Current Issue
Consultant Early View
Writing Clinic
Search
Login
Menu
Menu
Main navigation
Home
Featured Diseases & Conditions
Allergic Asthma
Alopecia Areata
Atopic Dermatitis Care
Alzheimer Disease
Chronic Kidney Disease
COVID-19
Depression Care
Emergency Medicine
Eosinophilic Disease
HIV Management
HIV Prevention
Multicancer Early Detection
Prostate Cancer
Scleroderma
Resources
AbbVie Partner Spotlight
Commentary
Disease State Directory
FDA Alerts
News
Pearls
Podcasts
Polls
Q&As
Quizzes
Slideshows
The 411 on a GLP-1
Videos
Events & Education
ACAAI Annual Scientific Meeting
ACR Convergence
Consultant360's Practical Updates in Primary Care
CME
International AIDS Conference
Publications
Advertising With Consultant360
Author Guidelines
Consultant Archive
Consultant Current Issue
Consultant Early View
Writing Clinic
Parathyroid Disorders
Resource Center
News
News
Resources
FDA Alerts
Pearls of Wisdom
From the Journal
Insights
Commentary
Podcasts
Q&As
Videos
Interactive
Polls
Quizzes
Slideshows
Events & Education
News
bone density
bone density
Disrupting sleep and circadian rhythms alters bone metabolism
08/09/2017
Circadian disruption and sleep restriction could lead to bone loss over time, with particularly strong effects in younger men, new research shows.
08/09/2017
FDA
FDA
FDA Approves New Option for Hyperparathyroidism
02/08/2017
The FDA approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease who are on hemodialysis.
02/08/2017
